Logo

Beckman Coulter Extends License to Critical Therapeutics' HMGB1 Technology

Feb 13, 2007
NEW YORK (GenomeWeb News) — Critical Therapeutics today said Beckman Coulter has exercised a licensing option to continue using its high mobility group box 1 technology.
 
CT said the companies penned a licensing deal in 2005 that gave BC the use of HMGB1 to develop an immunoassay to detect inflammatory diseases. HMGB1 has been identified as a possible mediator of tissue damage caused by inflammation.
 
Under the license, CT would receive a milestone payment on initial product sales and royalties on net sales, but specific financial terms of the agreement were not released.
 
CT CEO Frank Thomas said a HMBG1 blood-based test could be useful in diagnosing diseases such as multi-organ failure, sepsis, and inflammatory diseases such as rheumatoid arthritis.
 
CT also said it is working with MedImmune on an HMGB1 antibody clinical trials candidate.

Breaking News
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.